EUVIMEDEUVIMED entdecken
Crossref

Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma

Sonexai Kidoikhammouan, Worachart Lert-Itthiporn, Raksawan Deenonpoe, Charupong Saengboonmee, Sumalee Obchoei, Sopit Wongkham, Wunchana Seubwai

Anticancer Research · 2024

DOI: 10.21873/anticanres.17366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Sonexai Kidoikhammouan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand. Hauptthemen laut MEDLINE: Gemcitabine, Cholangiocarcinoma, Deoxycytidine, Drug Resistance, Neoplasm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineCholangiocarcinomaDeoxycytidineDrug Resistance, NeoplasmErbB ReceptorsBile Duct NeoplasmsHumansCell Line, TumorErlotinib HydrochlorideCell ProliferationPhosphorylationAntimetabolites, AntineoplasticCell CycleProtein Kinase InhibitorsAnimals

Stichwörter der Autor:innen

ChemosensitizingEGFRcholangiocarcinomadrug resistancegemcitabine

Substanzen

GemcitabineDeoxycytidineErbB ReceptorsEGFR protein, humanErlotinib HydrochlorideAntimetabolites, AntineoplasticProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand.
  • Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  • Division of Health and Applied Science, Faculty of Sciences, Prince of Songkla University, Hat Yai, Thailand.
  • Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; wunchana@kku.ac.th.

Zitieren

APA

Kidoikhammouan, S., Lert-Itthiporn, W., Deenonpoe, R., Saengboonmee, C., Obchoei, S., Wongkham, S., & Seubwai, W. (2024). Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17366

Vancouver

Kidoikhammouan S, Lert-Itthiporn W, Deenonpoe R, Saengboonmee C, Obchoei S, Wongkham S, et al. Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma. Anticancer Research. 2024. doi:10.21873/anticanres.17366

BibTeX
@article{Kidoikhammouan2024,
  author = {Kidoikhammouan, Sonexai and Lert-Itthiporn, Worachart and Deenonpoe, Raksawan and Saengboonmee, Charupong and Obchoei, Sumalee and Wongkham, Sopit and Seubwai, Wunchana},
  title = {Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17366}
}
Kostenlos starten →